Vitality Biopharma, Inc. focuses on developing cannabinoid pharmaceutical prodrugs in the United States. The company produces approximately 25 novel cannabosides, including glycosylated tetrahydrocannabinol (THC), cannabidiol, cannabidivarin, and cannabinol. It is developing THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome.

The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016.